La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Hanall Biopharma Bilan de santé
Santé financière contrôle des critères 6/6
Hanall Biopharma has a total shareholder equity of ₩178.2B and total debt of ₩0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are ₩221.5B and ₩43.3B respectively. Hanall Biopharma's EBIT is ₩3.6B making its interest coverage ratio -3.4. It has cash and short-term investments of ₩48.2B.
Informations clés
0%
Ratio d'endettement
₩0
Dette
Ratio de couverture des intérêts | -3.4x |
Argent liquide | ₩48.18b |
Fonds propres | ₩178.20b |
Total du passif | ₩43.31b |
Total des actifs | ₩221.52b |
Mises à jour récentes de la santé financière
Pas de mise à jour
Recent updates
Calculating The Intrinsic Value Of Hanall Biopharma Co., Ltd. (KRX:009420)
Jun 26Getting In Cheap On Hanall Biopharma Co., Ltd. (KRX:009420) Is Unlikely
May 22There May Be Underlying Issues With The Quality Of Hanall Biopharma's (KRX:009420) Earnings
Mar 13Introducing Hanall BiopharmaLtd (KRX:009420), The Stock That Zoomed 103% In The Last Five Years
Feb 12What Kind Of Investors Own Most Of Hanall Biopharma Co.,Ltd (KRX:009420)?
Jan 25Hanall Biopharma Co.,Ltd's (KRX:009420) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Jan 04Hanall BiopharmaLtd (KRX:009420) Is Growing Earnings But Are They A Good Guide?
Dec 14Here's Why We Think Hanall BiopharmaLtd (KRX:009420) Is Well Worth Watching
Nov 21Analyse de la situation financière
Passif à court terme: A009420's short term assets (₩103.8B) exceed its short term liabilities (₩29.7B).
Passif à long terme: A009420's short term assets (₩103.8B) exceed its long term liabilities (₩13.7B).
Historique et analyse du ratio d'endettement
Niveau d'endettement: A009420 is debt free.
Réduire la dette: A009420 had no debt 5 years ago.
Couverture de la dette: A009420 has no debt, therefore it does not need to be covered by operating cash flow.
Couverture des intérêts: A009420 has no debt, therefore coverage of interest payments is not a concern.